Targeting the KRAS G12C mutation in patients with advanced solid tumors
Hong, D.S.
Clinical Advances in Hematology and Oncology H&o 17(11): 612-614
2019
ISSN/ISBN: 1543-0790 PMID: 31851163 Document Number: 698017
Document emailed within 1 workday
Related Documents
Pu, X.-x.; Deng, Y.-h.; Xu, F.; Xiao, J.; Guo, H.-q.; Huang, H.; Tian, Y.; He, Y.-j.; Lin, T.-y. 2009: Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients Zhonghua Wei Chang Wai Ke Za Zhi 12(6): 594-597Chang, Y.-Y.; Lin, J.-K.; Lin, T.-C.; Chen, W.-S.; Jeng, K.-J.; Yang, S.-H.; Wang, H.-S.; Lan, Y.-T.; Lin, C.-C.; Liang, W.-Y.; Chang, S.-C. 2014: Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer Hepato-Gastroenterology 61(135): 1946-1953
Koike, J.; Ushigome, M.; Funahashi, K.; Shiokawa, H.; Kaneko, T.; Arai, K.; Matsuda, S.; Kagami, S.; Suzuki, T.; Kurihara, A.; Shimada, H.; Kaneko, H. 2014: Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer Hepato-Gastroenterology 61(136): 2222-2226
Mavroudis, D.; Kourousis, C.; Kakolyris, S.; Agelaki, S.; Kalbakis, K.; Androulakis, N.; Souglakos, J.; Vardakis, N.; Samonis, G.; Georgoulias, V. 2000: Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report Seminars in Oncology 27(1 Suppl. 2): 25-30
Gonçalves, A.; Braud, A.C.; Viret, F.; Genre, D.; Gravis, G.; Tarpin, C.; Giovannini, M.; Maraninchi, D.; Viens, P. 2003: Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors Anticancer Research 23(4): 3543-3548
Ran, S.; Gao, B.; Duffy, S.; Watkins, L.; Rote, N.; Thorpe, P.E. 1998: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature Cancer Research 58(20): 4646-4653
Bunganič, B.š; Hálková, T.; Benešová, L.; Belšánová, B.; Laclav, M.; Hrůzová, M.; Traboulsi, E.; Frič, P.ře.; Suchánek, Št.ěp.án.; Minárik, M.; Zavoral, M. 2016: KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass Casopis Lekaru Ceskych 155(1): 48-51
Tze-Er, K.; Ya-Chang, S.; Kun-Yeh, T.; Tien-Chang, J.; Jan-Gowth Chang 2010: Comparison of Two Different Screening Methods for the KRAS Mutation in Colorectal Cancer Clinical Laboratory 56(5-6): 175-186
Wadler, S.; Atkins, M.; Karp, D.; Neuberg, D.; Haynes, H.; Dutcher, J.P. 1998: Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991 Cancer Journal From Scientific American 4(4): 261-268
Sulka, W.; Godziński, J.; Rapała, M.; Klempous, J.; Stembalska, M. 1998: The surgical treatment of advanced stages of solid tumors in children Wiadomosci Lekarskie 51(Suppl 4): 174-177
Semino, C.; Martini, L.; Queirolo, P.; Cangemi, G.; Costa, R.; Alloisio, A.; Ferlazzo, G.; Sertoli, M.R.; Reali, U.M.; Ratto, G.B.; Melioli, G. 1999: Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience Anticancer Research 19(6c): 5645-5649
Hoorens, A.; Jouret-Mourin, A.; Sempoux, C.; Demetter, P.; De Hertogh, G.; Teugels, E. 2010: Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists Acta Gastro-Enterologica Belgica 73(4): 497-503
Bartholeyns, J.; Koch-Weser, J. 1981: Effects of alpha-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice, EMT6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats Cancer Research 41(12 Pt 1): 5158-5161
Lissoni, P.; Rovelli, F.; Tisi, E.; Brivio, F.; Ardizzoia, A.; Barni, S.; Tancini, G.; Saudelli, M.; Cesana, E.; Viganò, M.G. 1995: Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors Journal of Biological Regulators and Homeostatic Agents 9(4): 146-149
Feinstein, D.I. 2015: Disseminated intravascular coagulation in patients with solid tumors Oncology 29(2): 96-102
Rocha Lima, C.Max.; Leong, S-Swan.; Sherman, C.A.; Perkel, J.A.; Putman, T.; Safa, A.R.; Green, M.R. 2002: Irinotecan and gemcitabine in patients with solid tumors: phase I trial Oncology 16(5 Suppl. 5): 19-24
Moiceenko, V.M. 2004: Why doesn't overall survival improve in patients with disseminated solid tumors? Voprosy Onkologii 50(2): 149-156
Davey, R.A.; Milliken, S.T.; Harvie, R.M.; Cahill, E.J.; Morgan, L.J.; Kerestes, Z.; Levi, J.A. 1986: Serum galactosyltransferase as a prognostic marker in patients with solid tumors Cancer Research 46(11): 5973-5975
Weber, M. 2014: New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors Clinical Advances in Hematology and Oncology: H&o 12(12 Suppl 19: 12-17
Zander, A.R.; Spitzer, G.; Legha, S.; Dicke, D.A.; Verma, D.S.; Johnston, D.A.; Vellekoop, L.; Beran, M.; Schell, F.; Minnhaar, G.; Blumenschein, G.R.; Bodey, G.P. 1982: High-dose AMSA and bone marrow rescue in patients with solid tumors Cancer Treatment Reports 66(2): 385-386